Cargando…

Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition

Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and a...

Descripción completa

Detalles Bibliográficos
Autores principales: McNeill, Eoin P., Reese, Robert W., Tondon, Abishek, Clough, Bret H., Pan, Simin, Froese, Jeremiah, Palmer, Daniel, Krause, Ulf, Loeb, David M., Kaunas, Roland, Gregory, Carl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255770/
https://www.ncbi.nlm.nih.gov/pubmed/30478297
http://dx.doi.org/10.1038/s41419-018-1203-8
_version_ 1783374012949200896
author McNeill, Eoin P.
Reese, Robert W.
Tondon, Abishek
Clough, Bret H.
Pan, Simin
Froese, Jeremiah
Palmer, Daniel
Krause, Ulf
Loeb, David M.
Kaunas, Roland
Gregory, Carl A.
author_facet McNeill, Eoin P.
Reese, Robert W.
Tondon, Abishek
Clough, Bret H.
Pan, Simin
Froese, Jeremiah
Palmer, Daniel
Krause, Ulf
Loeb, David M.
Kaunas, Roland
Gregory, Carl A.
author_sort McNeill, Eoin P.
collection PubMed
description Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and associated morbidity. Furthermore, the OL microenvironment can support survival of tumor cells and resistance to chemotherapy. Therefore, a deeper understanding of OL formation and MBD progression is imperative for the development of future therapeutic strategies. Herein, we describe a novel in vitro platform to study bone–tumor interactions based on three-dimensional co-culture of osteogenically enhanced human mesenchymal stem cells (OEhMSCs) in a rotating wall vessel bioreactor (RWV) while attached to micro-carrier beads coated with extracellular matrix (ECM) composed of factors found in anabolic bone tissue. Osteoinhibition was recapitulated in this model by co-culturing the OEhMSCs with a bone–tumor cell line (MOSJ-Dkk1) that secretes the canonical Wnt (cWnt) inhibitor Dkk-1, a tumor-borne osteoinhibitory factor widely associated with several forms of MBD, or intact tumor fragments from Dkk-1 positive patient-derived xenografts (PDX). Using the model, we observed that depending on the conditions of growth, tumor cells can biochemically inhibit osteogenesis by disrupting cWnt activity in OEhMSCs, while simultaneously co-engrafting with OEhMSCs, displacing them from the niche, perturbing their activity, and promoting cell death. In the absence of detectable co-engraftment with OEhMSCs, Dkk-1 positive PDX fragments had the capacity to enhance OEhMSC proliferation while inhibiting their osteogenic differentiation. The model described has the capacity to provide new and quantifiable insights into the multiple pathological mechanisms of MBD that are not readily measured using monolayer culture or animal models.
format Online
Article
Text
id pubmed-6255770
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62557702018-11-27 Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition McNeill, Eoin P. Reese, Robert W. Tondon, Abishek Clough, Bret H. Pan, Simin Froese, Jeremiah Palmer, Daniel Krause, Ulf Loeb, David M. Kaunas, Roland Gregory, Carl A. Cell Death Dis Article Malignant bone disease (MBD) occurs when tumors establish in bone, causing catastrophic tissue damage as a result of accelerated bone destruction and inhibition of repair. The resultant so-called osteolytic lesions (OL) take the form of tumor-filled cavities in bone that cause pain, fractures, and associated morbidity. Furthermore, the OL microenvironment can support survival of tumor cells and resistance to chemotherapy. Therefore, a deeper understanding of OL formation and MBD progression is imperative for the development of future therapeutic strategies. Herein, we describe a novel in vitro platform to study bone–tumor interactions based on three-dimensional co-culture of osteogenically enhanced human mesenchymal stem cells (OEhMSCs) in a rotating wall vessel bioreactor (RWV) while attached to micro-carrier beads coated with extracellular matrix (ECM) composed of factors found in anabolic bone tissue. Osteoinhibition was recapitulated in this model by co-culturing the OEhMSCs with a bone–tumor cell line (MOSJ-Dkk1) that secretes the canonical Wnt (cWnt) inhibitor Dkk-1, a tumor-borne osteoinhibitory factor widely associated with several forms of MBD, or intact tumor fragments from Dkk-1 positive patient-derived xenografts (PDX). Using the model, we observed that depending on the conditions of growth, tumor cells can biochemically inhibit osteogenesis by disrupting cWnt activity in OEhMSCs, while simultaneously co-engrafting with OEhMSCs, displacing them from the niche, perturbing their activity, and promoting cell death. In the absence of detectable co-engraftment with OEhMSCs, Dkk-1 positive PDX fragments had the capacity to enhance OEhMSC proliferation while inhibiting their osteogenic differentiation. The model described has the capacity to provide new and quantifiable insights into the multiple pathological mechanisms of MBD that are not readily measured using monolayer culture or animal models. Nature Publishing Group UK 2018-11-26 /pmc/articles/PMC6255770/ /pubmed/30478297 http://dx.doi.org/10.1038/s41419-018-1203-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
McNeill, Eoin P.
Reese, Robert W.
Tondon, Abishek
Clough, Bret H.
Pan, Simin
Froese, Jeremiah
Palmer, Daniel
Krause, Ulf
Loeb, David M.
Kaunas, Roland
Gregory, Carl A.
Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title_full Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title_fullStr Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title_full_unstemmed Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title_short Three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
title_sort three-dimensional in vitro modeling of malignant bone disease recapitulates experimentally accessible mechanisms of osteoinhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255770/
https://www.ncbi.nlm.nih.gov/pubmed/30478297
http://dx.doi.org/10.1038/s41419-018-1203-8
work_keys_str_mv AT mcneilleoinp threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT reeserobertw threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT tondonabishek threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT cloughbreth threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT pansimin threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT froesejeremiah threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT palmerdaniel threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT krauseulf threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT loebdavidm threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT kaunasroland threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition
AT gregorycarla threedimensionalinvitromodelingofmalignantbonediseaserecapitulatesexperimentallyaccessiblemechanismsofosteoinhibition